Cisen Pharmaceutical Co., Ltd. (SHA:603367)
China · Delayed Price · Currency is CNY 12.77
-0.21 (-1.62%)
Nov 13, 2026, 3:00 PM CST
Cisen Pharmaceutical Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,120 | 1,214 | 1,165 | 983.39 | 997.95 | 938.98 |
Short-Term Investments | 253.16 | 461.47 | 357.58 | 154.11 | 236.27 | - |
Trading Asset Securities | 2,310 | 1,730 | 1,275 | 1,638 | 1,550 | 1,485 |
Cash & Short-Term Investments | 3,683 | 3,406 | 2,797 | 2,775 | 2,784 | 2,424 |
Cash Growth | 10.12% | 21.75% | 0.79% | -0.32% | 14.87% | -4.46% |
Accounts Receivable | 1,029 | 1,041 | 1,257 | 1,363 | 1,272 | 1,048 |
Other Receivables | 3.26 | 0.84 | 0.75 | 4.24 | 9.25 | 11.35 |
Receivables | 1,032 | 1,042 | 1,257 | 1,367 | 1,281 | 1,060 |
Inventory | 611.27 | 623.69 | 810.43 | 708.22 | 580.43 | 594.65 |
Other Current Assets | 419.7 | 138.78 | 96.74 | 119.41 | 99.63 | 66.45 |
Total Current Assets | 5,746 | 5,210 | 4,962 | 4,970 | 4,745 | 4,145 |
Property, Plant & Equipment | 1,543 | 1,675 | 1,546 | 1,390 | 1,489 | 1,591 |
Long-Term Investments | 5.53 | 390.03 | 665.08 | 602.27 | 265.08 | 308.01 |
Other Intangible Assets | 194.82 | 196.29 | 203.97 | 211.6 | 213.03 | 210.82 |
Long-Term Deferred Tax Assets | 70.93 | 78.34 | 77.41 | 79.83 | 86.72 | 81.65 |
Long-Term Deferred Charges | - | - | 0.47 | 1.91 | 3.86 | 2.05 |
Other Long-Term Assets | 179.15 | 47.89 | 99.14 | 81.94 | 12.87 | 25.54 |
Total Assets | 7,740 | 7,597 | 7,554 | 7,338 | 6,815 | 6,364 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 652.22 | 620.31 | 549.49 | 468.01 | 459.71 | 434.97 |
Accrued Expenses | 77.92 | 233.37 | 329.92 | 139.77 | 259.48 | 214.52 |
Short-Term Debt | 4.47 | 12.08 | 71.98 | 34.8 | 57.79 | 130 |
Current Portion of Long-Term Debt | - | - | 32.63 | - | - | - |
Current Portion of Leases | 1.16 | 2.04 | 2.64 | 3.34 | 0.3 | 2.72 |
Current Income Taxes Payable | 48.99 | 6.28 | 11.71 | 34.67 | 5.61 | 1.18 |
Current Unearned Revenue | 94.7 | 64.35 | 78.11 | 100.16 | 118.78 | 70.05 |
Other Current Liabilities | 335.59 | 285.34 | 412.36 | 589.17 | 380.24 | 365.5 |
Total Current Liabilities | 1,215 | 1,224 | 1,489 | 1,370 | 1,282 | 1,219 |
Long-Term Debt | 19.47 | 25.79 | 7.7 | 128.5 | 100 | - |
Long-Term Leases | 1.6 | 3.61 | 0.89 | 4.03 | 0.51 | 10.91 |
Long-Term Unearned Revenue | 87.21 | 94.04 | 57.17 | 56.25 | 65.36 | 74.43 |
Long-Term Deferred Tax Liabilities | 6.41 | 19.54 | 12.28 | 12.68 | 11.46 | 3.87 |
Total Liabilities | 1,330 | 1,367 | 1,567 | 1,571 | 1,459 | 1,308 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 452.75 | 452.75 | 452.75 | 452.78 | 453.31 | 453.33 |
Additional Paid-In Capital | 1,934 | 1,934 | 1,929 | 1,919 | 1,913 | 1,863 |
Retained Earnings | 3,984 | 3,807 | 3,570 | 3,358 | 2,989 | 2,774 |
Treasury Stock | - | - | - | -0.08 | -19.77 | -32.74 |
Comprehensive Income & Other | -3.93 | -2.65 | -2.71 | -2.69 | -2.93 | -3.07 |
Total Common Equity | 6,367 | 6,191 | 5,950 | 5,727 | 5,332 | 5,055 |
Minority Interest | 42.44 | 39.52 | 37.39 | 39.1 | 23.64 | 0.75 |
Shareholders' Equity | 6,410 | 6,231 | 5,987 | 5,766 | 5,356 | 5,056 |
Total Liabilities & Equity | 7,740 | 7,597 | 7,554 | 7,338 | 6,815 | 6,364 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 26.71 | 43.53 | 115.83 | 170.67 | 158.61 | 143.63 |
Net Cash (Debt) | 3,657 | 3,362 | 2,681 | 2,604 | 2,625 | 2,280 |
Net Cash Growth | 10.74% | 25.39% | 2.95% | -0.79% | 15.15% | 3.32% |
Net Cash Per Share | 8.11 | 7.42 | 5.90 | 5.75 | 5.78 | 5.05 |
Filing Date Shares Outstanding | 452.75 | 452.75 | 452.75 | 452.76 | 451.36 | 449.83 |
Total Common Shares Outstanding | 452.75 | 452.75 | 452.75 | 452.76 | 451.34 | 449.83 |
Working Capital | 4,531 | 3,986 | 3,473 | 3,600 | 3,463 | 2,926 |
Book Value Per Share | 14.06 | 13.67 | 13.14 | 12.65 | 11.81 | 11.24 |
Tangible Book Value | 6,173 | 5,995 | 5,746 | 5,516 | 5,119 | 4,844 |
Tangible Book Value Per Share | 13.63 | 13.24 | 12.69 | 12.18 | 11.34 | 10.77 |
Buildings | - | 1,412 | 1,277 | 1,275 | 1,188 | 1,191 |
Machinery | - | 2,469 | 2,109 | 2,092 | 1,903 | 1,797 |
Construction In Progress | - | 163.6 | 405.8 | 66.68 | 207.17 | 199.71 |